Big pharma Bristol-Myers Squibb’s (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a kidney-cancer trial, driving its embattled stock up 50%. Bristol-Myers’ trial, called Checkmate-025, compared Opdivo with everolimus, better known as Novartis’ (NVS) Afinitor, in patients with advanced or
The size, scope and cost of Sprint’s latest network upgrade has Wall Street on edge, though some analysts are upbeat on the struggling wireless firms’ chances of finally matching or overtaking rivals in service quality, at least in some urban markets. Sprint (S) reports Q2 earnings on Aug. 5. Uppermost on analysts’ concerns is how Sprint will finance the next stage in a multiyear network upgrade and radio spectrum purchases it’s likely to make in
Yahoo (YHOO) reports Q2 earnings after the close Tuesday, and analysts say it looks like a “lackluster” quarter as the Web portal’s signature display ad business continues to struggle, although its mobile share is picking up. Analysts also want a final answer regarding the outcome of the planned spinoff of Yahoo’s 15% stake in China giant Alibaba Group (BABA). That tax-free spinoff, announced in February, is a high-profile must-do for Yahoo CEO